We observed that AML disease burden (by measuring GFP+ cells in the BM) was accelerated in Atg16L1E230– mice compared with WT controls (Atg16L1E230+) as determined on days 14 and 20 after injection with MN1-driven AML (Figure 2B). Here, MN1 is linked to acute myeloid leukemia.